The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000.
Pharmacoeconomics. 2012.
PMID: 22974536